200 related articles for article (PubMed ID: 30858682)
1. A phase 2 randomized, double-masked, placebo-controlled study of novel nonsystemic kinase inhibitor TOP1630 for the treatment of dry eye disease.
Taylor M; Ousler G; Torkildsen G; Walshe C; Fyfe MCT; Rowley A; Webber S; Sheppard JD; Duggal A
Clin Ophthalmol; 2019; 13():261-275. PubMed ID: 30858682
[TBL] [Abstract][Full Text] [Related]
2. TNF-α inhibitor tanfanercept (HBM9036) improves signs and symptoms of dry eye in a phase 2 trial in the controlled adverse environment in China.
Dong Y; Wang S; Cong L; Zhang T; Cheng J; Yang N; Qu X; Li D; Zhou X; Wang H; Lee M; Wang M; Chen S; Ousler GW; Chen X; Xie L
Int Ophthalmol; 2022 Aug; 42(8):2459-2472. PubMed ID: 35192105
[TBL] [Abstract][Full Text] [Related]
3. Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye Disease: Results of the Randomized Phase III OPUS-2 Study.
Tauber J; Karpecki P; Latkany R; Luchs J; Martel J; Sall K; Raychaudhuri A; Smith V; Semba CP;
Ophthalmology; 2015 Dec; 122(12):2423-31. PubMed ID: 26365210
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Trial of Topical Fibrinogen-Depleted Human Platelet Lysate Treatment of Dry Eye Secondary to Chronic Graft-versus-Host Disease.
Sugar A; Hussain M; Chamberlain W; Dana R; Kelly DP; Ta C; Irvine J; Daluvoy M; Perez V; Olson J; Jhanji V; Walts TA; Stulting RD; Waller EK; Jagirdar N;
Ophthalmol Sci; 2022 Sep; 2(3):100176. PubMed ID: 36245754
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of MIM-D3 ophthalmic solutions in a randomized, placebo-controlled Phase 2 clinical trial in patients with dry eye.
Meerovitch K; Torkildsen G; Lonsdale J; Goldfarb H; Lama T; Cumberlidge G; Ousler GW
Clin Ophthalmol; 2013; 7():1275-85. PubMed ID: 23836957
[TBL] [Abstract][Full Text] [Related]
6. A Phase 2 Trial to Test Safety and Efficacy of ST-100, a Unique Collagen Mimetic Peptide Ophthalmic Solution for Dry Eye Disease.
Baratta RO; Schlumpf E; Del Buono BJ; DeLorey S; Ousler G; Calkins DJ
Ophthalmol Sci; 2024; 4(3):100451. PubMed ID: 38317866
[TBL] [Abstract][Full Text] [Related]
7. A Phase II, Multicenter, Randomized, Placebo-Controlled, Double-Masked Trial of a Topical Estradiol Ophthalmic Formulation in Postmenopausal Women with Moderate-to-Severe Dry Eye Disease.
Schmidl D; Szalai L; Kiss OG; Schmetterer L; Garhöfer G
Adv Ther; 2021 Apr; 38(4):1975-1986. PubMed ID: 33710587
[TBL] [Abstract][Full Text] [Related]
8. Lifitegrast ophthalmic solution 5.0% for treatment of dry eye disease: results of the OPUS-1 phase 3 study.
Sheppard JD; Torkildsen GL; Lonsdale JD; D'Ambrosio FA; McLaurin EB; Eiferman RA; Kennedy KS; Semba CP;
Ophthalmology; 2014 Feb; 121(2):475-83. PubMed ID: 24289915
[TBL] [Abstract][Full Text] [Related]
9. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
Clark D; Sheppard J; Brady TC
J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
[No Abstract] [Full Text] [Related]
10. Efficacy and Safety of the Melanocortin Pan-Agonist PL9643 in a Phase 2 Study of Patients with Dry Eye Disease.
Evans D; Kenyon K; Ousler G; Watson M; Vollmer P; McLaurin EB; Torkildsen G; Winters J; Dodd J; Jordan R; Wills ST; Spana C
J Ocul Pharmacol Ther; 2023 Nov; 39(9):600-610. PubMed ID: 37677000
[No Abstract] [Full Text] [Related]
11. Lifitegrast for the Treatment of Dry Eye Disease: Results of a Phase III, Randomized, Double-Masked, Placebo-Controlled Trial (OPUS-3).
Holland EJ; Luchs J; Karpecki PM; Nichols KK; Jackson MA; Sall K; Tauber J; Roy M; Raychaudhuri A; Shojaei A
Ophthalmology; 2017 Jan; 124(1):53-60. PubMed ID: 28079022
[TBL] [Abstract][Full Text] [Related]
12. A Clinical Phase II Study to Assess Efficacy, Safety, and Tolerability of Waterfree Cyclosporine Formulation for Treatment of Dry Eye Disease.
Wirta DL; Torkildsen GL; Moreira HR; Lonsdale JD; Ciolino JB; Jentsch G; Beckert M; Ousler GW; Steven P; Krösser S
Ophthalmology; 2019 Jun; 126(6):792-800. PubMed ID: 30703441
[TBL] [Abstract][Full Text] [Related]
13. A Phase II/III, randomized, double-masked, vehicle-controlled, dose-ranging study of the safety and efficacy of OTX-101 in the treatment of dry eye disease.
Tauber J; Schechter BA; Bacharach J; Toyos MM; Smyth-Medina R; Weiss SL; Luchs JI
Clin Ophthalmol; 2018; 12():1921-1929. PubMed ID: 30323548
[TBL] [Abstract][Full Text] [Related]
14. Tofacitinib (CP-690,550), a Janus kinase inhibitor for dry eye disease: results from a phase 1/2 trial.
Liew SH; Nichols KK; Klamerus KJ; Li JZ; Zhang M; Foulks GN
Ophthalmology; 2012 Jul; 119(7):1328-35. PubMed ID: 22525048
[TBL] [Abstract][Full Text] [Related]
15. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model.
Sosne G; Ousler GW
Clin Ophthalmol; 2015; 9():877-84. PubMed ID: 26056426
[TBL] [Abstract][Full Text] [Related]
16. A Phase 3, Randomized, Double-Masked Study of OTX-101 Ophthalmic Solution 0.09% in the Treatment of Dry Eye Disease.
Goldberg DF; Malhotra RP; Schechter BA; Justice A; Weiss SL; Sheppard JD
Ophthalmology; 2019 Sep; 126(9):1230-1237. PubMed ID: 30965064
[TBL] [Abstract][Full Text] [Related]
17. A phase 2 randomized, double-masked, placebo-controlled study of a novel integrin antagonist (SAR 1118) for the treatment of dry eye.
Semba CP; Torkildsen GL; Lonsdale JD; McLaurin EB; Geffin JA; Mundorf TK; Kennedy KS; Ousler GW
Am J Ophthalmol; 2012 Jun; 153(6):1050-60.e1. PubMed ID: 22330307
[TBL] [Abstract][Full Text] [Related]
18. Rebamipide (OPC-12759) in the treatment of dry eye: a randomized, double-masked, multicenter, placebo-controlled phase II study.
Kinoshita S; Awamura S; Oshiden K; Nakamichi N; Suzuki H; Yokoi N;
Ophthalmology; 2012 Dec; 119(12):2471-8. PubMed ID: 23009892
[TBL] [Abstract][Full Text] [Related]
19. Multicenter Study of a Novel Topical Interleukin-1 Receptor Inhibitor, Isunakinra, in Subjects With Moderate to Severe Dry Eye Disease.
Goldstein MH; Martel JR; Sall K; Goldberg DF; Abrams M; Rubin J; Sheppard J; Tauber J; Korenfeld M; Agahigian J; Durham TA; Furfine E
Eye Contact Lens; 2017 Sep; 43(5):287-296. PubMed ID: 27466718
[TBL] [Abstract][Full Text] [Related]
20. Lifitegrast Ophthalmic Solution 5% Is a Safe and Efficient Eyedrop for Dry Eye Disease: A Systematic Review and Meta-Analysis.
Li JX; Tsai YY; Lai CT; Li YL; Wu YH; Chiang CC
J Clin Med; 2022 Aug; 11(17):. PubMed ID: 36078948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
